Haddad Raymond N, Karmustaji Fatema, Alloush Rasha, Al Soufi Mahmoud, Kasem Mohamed
M3C-Necker, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates.
Front Cardiovasc Med. 2024 Jan 31;11:1332152. doi: 10.3389/fcvm.2024.1332152. eCollection 2024.
Axillary arterial access (AAA) in pediatric heart catheterizations is undervalued.
We retrospectively reviewed children with congenital heart diseases (CHDs) who received trans-axillary arterial catheterizations between January 2019 and February 2023. We aimed ultrasound-guided punctures in the proximal two-thirds of axillary arteries with diameters ≥2 mm to insert 7 cm/4 Fr short introducers. We administrated intra-arterial verapamil (1.25 mg) and heparin (100 UI/kg). We infiltrated per-operatively 2% lignocaine (10 mg) for arterial spasms, long sheaths use (≥5 Fr), and ≥60 min procedures in <3 kg patients.
We identified 30 patients (66.7% males) with a median age of 1.1 months (IQR, 0.3-5.4), and a median weight of 3.1 kg (IQR, 2.7-3.7). 5/30 patients had six redo interventions after a median of 3.9 months (IQR, 1.7-5.1). Overall, 27/36 procedures were interventional, including 6 aortic valvuloplasties, 6 balloon angioplasties, and 15 stenting procedures. The median arterial axillary angiographic diameter was 2.6 mm (IQR, 2.4-3). Access was right-sided in 23/36 (63.9%) procedures and obtained using 21G/2.5 cm bevel needles in 25/36 (69.4%) procedures. No hemodynamical change occurred after introducing spasmolytic drugs. The median fluoroscopy time was 26.1 min (IQR, 19.2-34.8). There were two self-resolving arterial dissections, one sub-occlusive arterial thrombosis (resolved with 6 weeks of enoxaparin), and one occlusive arterial thrombosis (resolved with alteplase thrombolysis and 6 weeks of enoxaparin). Median follow-up was 11.7 months (IQR, 8-17.5). Four patients with complex univentricular hearts died from non-procedural causes at a median of 40 days (IQR, 31-161) postoperative.
Systematic approach for AAA is the key to success and unlocks the many potentials of trans-axillary pediatric cardiology interventions.
小儿心脏导管插入术中腋动脉入路(AAA)未得到充分重视。
我们回顾性分析了2019年1月至2023年2月期间接受经腋动脉导管插入术的先天性心脏病(CHD)患儿。我们的目标是在直径≥2 mm的腋动脉近端三分之二处进行超声引导穿刺,以插入7 cm/4 Fr的短导管鞘。我们给予动脉内维拉帕米(1.25 mg)和肝素(100 UI/kg)。对于体重<3 kg的患者,术中使用2%利多卡因(10 mg)浸润以预防动脉痉挛、使用长导管鞘(≥5 Fr)以及手术时间≥60分钟的情况。
我们确定了30例患者(66.7%为男性),中位年龄为1.1个月(四分位间距,0.3 - 5.4),中位体重为3.1 kg(四分位间距,2.7 - 3.7)。5/30例患者在中位3.9个月(四分位间距,1.7 - 5.1)后进行了6次再次干预。总体而言,36例手术中有27例为介入性手术,包括6例主动脉瓣成形术、6例球囊血管成形术和15例支架置入术。腋动脉造影的中位直径为2.6 mm(四分位间距,2.4 - 3)。36例手术中有23例(63.9%)入路为右侧,36例手术中有25例(69.4%)使用21G/2.5 cm斜面针获得入路。引入解痉药物后未发生血流动力学变化。中位透视时间为26.1分钟(四分位间距,19.2 - 34.8)。发生了2例自行缓解的动脉夹层、1例亚闭塞性动脉血栓形成(使用依诺肝素6周后缓解)和1例闭塞性动脉血栓形成(使用阿替普酶溶栓及依诺肝素6周后缓解)。中位随访时间为11.7个月(四分位间距,8 - 17.5)。4例复杂单心室心脏患者术后中位40天(四分位间距,31 - 161)因非手术原因死亡。
AAA的系统方法是成功的关键,并开启了经腋小儿心脏病介入治疗的诸多潜力。